छोड़कर सामग्री पर जाएँ

Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma

Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.

Read More

​ Indian generic companies have benefited from the continuing shortages and approval slowdown in the US. Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी